 NEW YORK, Sept. 20, 2021 GLOBE NEWSWIRE -- BeyondSpring Pharmaceuticals the Company or BeyondSpring NASDAQ: BYSI, a global pharmaceutical company focused on the development of cancer therapeutics, today will have a late-breaking oral presentation at the European Society for Medical Oncology 2021 Congress. This includes the final intention-to-treat ITT dataset from the Companys DUBLIN-3 Phase 3 registrational trial of its first-in-class lead asset, plinabulin, in combination with docetaxel vs. docetaxel alone for the treatment of 2nd3rd line non-small cell lung cancer NSCLC patients with EGFR wild type. Plinabulin is a selective immunomodulating microtubule-binding agent SIMBA, which is a potent antigen presenting cell APC inducer. 